Join Growin Stock Community!

Leap therapeutics, inc.LPTX.US Overview

US StockHealthcare
(No presentation for LPTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LPTX AI Insights

LPTX Overall Performance

LPTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LPTX Recent Performance

3.69%

Leap therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

LPTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LPTX Key Information

LPTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LPTX Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Price of LPTX

LPTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LPTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is LPTX's latest earnings report released?

    The most recent financial report for Leap therapeutics, inc. (LPTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LPTX's short-term business performance and financial health. For the latest updates on LPTX's earnings releases, visit this page regularly.

  • How much cash does LPTX have?

    At the end of the period, Leap therapeutics, inc. (LPTX) held Total Cash and Cash Equivalents of 10.47M, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LPTX go with three margins increasing?

    In the latest report, Leap therapeutics, inc. (LPTX) did not achieve the “three margins increasing” benchmark, with a gross margin of -9,631.58%%, operating margin of -13,330.62%%, and net margin of -12,425.36%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LPTX's profit trajectory and future growth potential.

  • Is LPTX's EPS continuing to grow?

    According to the past four quarterly reports, Leap therapeutics, inc. (LPTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LPTX?

    Leap therapeutics, inc. (LPTX)'s Free Cash Flow (FCF) for the period is -8.32M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 46.69% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LPTX?

    The latest valuation data shows Leap therapeutics, inc. (LPTX) has a Price-To-Earnings (PE) ratio of -2.29 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.